The discovery of the correlation between mRNA level of MD2 and the resistance to chemotherapy and radiotherapy may promote further investigations on the mechanism of drug-resistance in glioma patients, which could better direct clinical practice. This evidence concerns the gene LY96 and central nervous system cancer.